Oncolytics Biotech (ONCY) Other Working Capital Changes (2018 - 2025)
Oncolytics Biotech (ONCY) posted quarterly Other Working Capital Changes of -$73390.1 for Q3 2025, down 25.14% year-over-year from -$98042.5 in Q3 2024, and little changed quarter-over-quarter from -$73614.7 in Q2 2025.
Oncolytics Biotech (ONCY) Other Working Capital Changes (2018 - 2025) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Other Working Capital Changes for 8 consecutive years, with -$73390.1 the latest figure, recorded in Q3 2025.
- In Q3 2025, Other Working Capital Changes fell 25.14% year-over-year to -$73390.1; the TTM figure through Sep 2025 stood at -$290372.1 (down 12.11% YoY), while the FY2025 annual figure was -$293000.0, down 15.81% from the prior year.
- Other Working Capital Changes was little changed at -$73390.1 in Q3 2025 per ONCY's latest filing, from -$73614.7 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at -$47524.1 in Q2 2024 and bottomed at -$88232.7 in Q1 2021.
- Historically, Other Working Capital Changes has averaged -$71534.8 across 5 years, with a median of -$73607.6 in 2022.
- Annual changes were most pronounced in 2024 — Other Working Capital Changes jumped 36.16% — and 2025, when it tumbled 54.9%.
- Oncolytics Biotech's Other Working Capital Changes stood at -$63862.0 in 2021, then dropped by 17.67% to -$75143.7 in 2022, then declined by 1.66% to -$76391.7 in 2023, then gained by 6.29% to -$71584.9 in 2024, then slipped by 2.52% to -$73390.1 in 2025.
- Business Quant data shows ONCY's Other Working Capital Changes at -$73390.1 in Q3 2025, -$73614.7 in Q2 2025, and -$71782.4 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Oncolytics Biotech | 101.16 Mn | 101.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -73,390.14 |
| Sep 30, 2025 | -73,390.14 |
| Sep 30, 2025 | -73,390.14 |
| Jun 30, 2025 | -73,614.67 |
| Jun 30, 2025 | -73,614.67 |
| Jun 30, 2025 | -73,614.67 |
| Mar 31, 2025 | -71,782.40 |
| Mar 31, 2025 | -71,782.40 |
| Mar 31, 2025 | -71,782.40 |
| Dec 31, 2024 | -71,584.91 |
| Dec 31, 2024 | -71,584.91 |
| Dec 31, 2024 | -71,584.91 |
| Sep 30, 2024 | -58,644.27 |
| Sep 30, 2024 | -58,644.27 |
| Sep 30, 2024 | -58,644.27 |
| Jun 30, 2024 | -47,524.14 |
| Jun 30, 2024 | -47,524.14 |
| Jun 30, 2024 | -47,524.14 |
| Mar 31, 2024 | -76,437.66 |
| Mar 31, 2024 | -76,437.66 |